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Procoagulant or impaired fibrinolytic states as well as
inflammatory reactions mediated by cytokines are likely
involved in the pathogenesis of acute ischemic stroke. We
examined the potential relationship between interleukin 6
(IL-6) and hemostatic markers. The procoagulant and fibrinoly-
tic states were assessed in 46 patients with acute stroke by
measuring plasma levels of plasminogen activator inhibitor-1
(PAI-1), thrombin-antithrombin complex (TAT), and plasmino-
gen-antiplasmin complex (PAP). Circulating IL-6 levels were
measured using ELISA (Quantikine, R & D systems, MN,
USA). Circulating IL-6 (mean, 26.5 pg/mL) and PAI-1 (mean,
19.9 ng/mL) levels were higher in patients with acute stroke
than in healthy subjects (mean, 3.0 pg/mL, 10.4 ng/mL, respec-
tively). TAT levels were statistically different according to the
etiologic subtypes of stroke (atherogenic, 2.5 ng/mL; lacunar
3.2 ng/mL; cardiogenic 9.9 ng/mL, p = 0.021). Neither procoa-
gulant levels nor fibrinolytic markers significantly correlated
with circulating IL-6 levels. Our findings suggest that elevated
proinflammatory cytokines during the initial hours of ischemic
stroke may be an independent pathogenic factor or a conse-
quence of the thrombotic event with no relationship to the
procoagulant or fibrinolytic states.
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INTRODUCTION
Atherosclerosis is the main cause of cerebral
infarction.1 The revised response to injury hypo-
thesis highlights the importance of inflammatory
reactions involved in the pathogenesis of athero-
sclerosis.2 Injury of endothelial cells may alter the
balance of procoagulant and antithrombotic fac-
tors on the surface of endothelium to favor throm-
bosis.3 Consonant with the role of monocytes/
macrophages, vascular smooth muscle cells and
platelets, there are several important interactions
between the blood components of both the coag-
ulation and fibrinolytic systems.4 Thus, a growing
body of evidence supports a relationship between
the inflammatory response, thrombosis, and the
development of atherosclerotic lesions.5 In addi-
tion, monocyte-derived cytokines, such as IL-6,
are in part responsible for the elevations of
plasma fibrinogen that accompany inflammation.
To better understand the relationship between the
inflammatory response and thrombosis in is-
chemic stroke, we assessed procoagulant and
fibrinolytic states in patients with acute ischemic
stroke by measuring plasma levels of plasminogen
activator inhibitor-1 (PAI-1), thrombin-antithrom-
bin complex (TAT) and plasminogen-antiplasmin
complex (PAP), and examined the potential rela-
tionship between these hemostatic markers and
interleukin 6 (IL-6).
MATERIALS AND METHODS
Forty-six patients (34 men and 12 women, mean
age, 64 yrs) presenting with acute ischemic stroke
were studied according to a standard protocol
entailing clinical and imaging studies (CT, MRI
and/or angiography) of the brain. Patients were
admitted with atherosclerotic (n = 28), lacunar (n=
14), and cardioembolic (n = 4) infarcts within the
first 24 hours, and 28 age- and sex- matched
healthy subjects were included for comparison
Plasma Level of IL-6 and Its Relationship to Procoagulant
and Fibrinolytic Markers in Acute Ischemic Stroke
Jae Woo Song,1 Kyung Soon Song,1 Jong Rak Choi,1 Shin Young Kim,1 and Ji-Hyuk Rhee2
Departments of 1Laboratory Medicine and 2Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Received September 28, 2005
Accepted October 27, 2005
This study was supported by the Brain Korea 21 Project for
Medical Science, Yonsei University, 2001.
Reprint address: requests to Dr. Jong Rak Choi, Department of
Laboratory Medicine, Yonsei University College of Medicine, 134
Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-
2228-2445, Fax: 82-2-364-1583, E-mail: cjr0606@yumc.yonsei.ac.kr
Jae Woo Song, et al.
Yonsei Med J Vol. 47, No. 2, 2006
(Table 1). Citrated blood was drawn early in the
morning on admission to determine plasma levels
of TAT (Dade-Behring, Germany), PAP (Dade-
Behring, Germany), PAI-1 (Diagnostica Stago,
France), IL-6 (Quantikine, R&D systems, MN,
USA), and anti-phospholipid antibody (IgG/IgM
Diagnostica Stago, France) by ELISA methods.
RESULTS
Circulating IL-6 levels (mean, 26.5 pg/mL, range,
6.4-161.3 pg/mL) were significantly higher in all
patients with acute stroke than in healthy subjects
(median, 3.0 pg/mL, range, 2.3-5.9 pg/mL) (p <
0.001, Table 2).
PAI-1 and PAP levels were also significantly
different between patients with acute stroke (mean,
19.9 ng/mL, 522.9 ng/mL, respectively) and healthy
subjects (mean 10.4 ng/mL, 240.4 ng/mL, respec-
tively) (p < 0.001, Table 2).
Mean levels of TAT (3.4 ng/mL) in the stroke
patient group were not significantly increased
compared with normal subjects (2.8 ng/mL) (p <
0.001, Table 2), however, TAT levels were sta-
tistically different according to the etiologic sub-
types of stroke (atherogenic, 2.5 ng/mL; lacunar
3.2 ng/mL; cardiogenic, 9.9 mg/mL; p = 0.021).
PAI-1 and PAP levels were higher in the
lacunar subtype and in the cardiogenic subtype,
respectively, than in other subtypes, with weak
statistical significance (p = 0.070 and p = 0.058, re-
spectively). However, there were no significant
differences in levels of IL-6 and other hemostatic
markers among the different types of stroke
(Table 3).
Levels of IL-6 and hemostatic parameters were
not different between positive and negative
groups for anti-phospholipid antibodies (Table 4).
There were significant correlations between
TAT and PAP markers (r = 0.455, p = 0.0015), and
TAT correlated weakly with PAI-1 (r=0.264, p =
0.0787). However, neither procoagulant nor
fibrinolytic markers were significantly correlated
with circulating IL-6 levels (Table 5).
Table 1. Characteristics of Study Groups
Characteristics Stroke (n = 46) Controls (n = 28)
Age (yrs)
Mean ± SD 63.7 ± 7.3 59.6 ± 8.0
Range 36 - 89 43 - 76
Men/women (n) 34/12 20/8
Smokers (n) 22 9
Hypertension (n) 30 11
Diabetes mellitus (n) 7* 0
Ischemic heart disease (n) 4 0
Medications used
Antihypertensive drugs 27 10
Anticoagulants 4 0
Aspirin 11* 0
Infections 3 0
Other illness 8* 0
*p<0.05 versus control group.
Other illness: chronic bronchitis, hyperthyroidism, multiple osteoarthritis, fatty liver, proteinuria, glaucoma, oral ulcer/gingivitis,
degenerative spondylosis.
Tabel 4. Circulating Levels of Cytokines and Hemostatic Parameters According to the Positivity (IgG or IgM) for
Anti-phospholipid Antibody
Parameters
Anti-phospholipid antibody
Positive (n = 18) Negative (n = 28) p value*
Sex (M/F) 14/4 20/8 0.739
IL-6 (pg/mL) 31.8 (36.7) 39.8 (43.8) 0.510
PAI-1 (ng/mL) 18.8 (10.2) 20.5 (10.1) 0.597
PAP (ng/mL) 446.8 (197.3) 571.8 (430.2) 0.189
TAT (ng/mL) 2.6 (1.7) 3.9 (4.7) 0.193
Values are given as number of subjects or mean values (SD).
*Chi-square test for categorical and Mann-Whitney test for continuous variables were used.
Data on PAI-1 were missing in 1 positive APA.
Abbreviations: see Table 2.
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Table 2. Plasma Concentrations of IL-6 and PAI-1 in Patients with Acute Ischemic Stroke and Healthy Subjects
Variables Stroke (n = 46) Healthy subjects (n = 28) p value*
IL-6 (pg/mL) 26.5 (6.4 - 161.3) 3.0 (2.3 - 5.9) < 0.001
PAI-1 (ng/mL) 19.9 (3.3 - 56.7) 10.4 (1.3 - 23.1) < 0.001
TAT (ng/mL) 3.4 (1.1 - 24.5) 2.8 (1.6 - 4.0) 0.071
PAP (ng/mL) 522.9 (163 - 2182) 240.4 (120 - 700) < 0.001
Values are expressed as mean (range).
*Mann-Whitney test was used.
Data on PAI-1 were missing in one stroke patient.
Abbreviations: IL-6, interleukin-6; PAI, plasminogen activator inhibitor; TAT, thrombin-antithrombin; PAP, plasmin-antiplasmin.
Table 3. Circulating Levels of Hemostatic Parameters According to the Etiologic Subtypes of Acute Ischemic Stroke
Parameters All patients Atherogenic (n = 28) Lacunar (n = 14) Cardiogenic (n = 4) p value*
PAI-1 (ng/mL) 19.9 (3.3 - 56.7) 17.1 (3.3 - 33.5) 24.6 (7.7 - 56.7) 22.1 (19.8 - 23.8) 0.070
PAP (ng/mL) 522.9 (163 - 2182) 476.2 (163 - 1028) 403.5 (209 - 698) 1268.0 (366 - 2182) 0.058
TAT (ng/mL) 3.4 (1.1 - 24.5) 2.5 (1.1 - 8.6) 3.2 (1.4 - 13.2) 9.9 (3.9 - 24.5) 0.021
APA 0.510
Positive 18 12 6 0
Negative 28 16 8 4
Values are given as number of subjects or mean (range).
*Chi-square test for categorical and ANOVA test for continuous variables were used.
Data on PAI-1 were missing in one cardiogenic subtypes.
Abbreviations: IL-6, interleukin-6; PAP, plasmin inhibitor complex; TAT, thrombin-antithrombin complex; PAI, plasminogen activator
inhibitor; APA anti-phospholipid antibody (IgG of IgM).
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DISCUSSION
Elevated plasma fibrinogen is a recognized risk
factor for stroke6 and elevations in fibrinogen may
in fact be a surrogate for elevated IL-6, a cytokine
which plays a critical role in regulating fibrinogen
production.7 IL-6 levels have also been reported to
be elevated in stroke patients,8-10 and the increase
of IL-6 significantly correlated with increased
brain lesion volumes and was associated with
poor functional and neurological outcome.9 In
addition to elevated IL-6 levels in patients, gene
expression of interleukin-1β (IL-1 ) and TNF- inβ α
rats are elevated after cerebral infarction.11 IL-6
also regulates the production of tumor necrosis
factor (TNF- ),α 12 which in turn is capable of
inducing tissue factor-like procoagulant activity
on the surface of endothelial cells.13 In addition,
these mediators activate the hepatic synthesis of
acute-phase reactants such as C-reactive protein,
serum amyloid A protein, fibrinogen, haptoglobin,
ceruloplasmin, and C4b-binding protein (C4b-
BP).
11,14
C4b-BP possesses a binding site for pro-
tein S, a cofactor for protein C, and another
natural anticoagulant which inactivates factors Va
and VIIIa.15 In fact, during stroke, C4b-BP causes
a decrease of free protein S,16 which may promote
a procoagulant state. As a result, IL-6 may influ-
ence the disease course in the stroke by changing
coagulation and fibrinolysis, in addition to cau-
sing hemorheologic changes by increasing fibrino-
gen levels and blood viscosity.17 Therefore, the
aim of this study was to assess the relationship
between circulating levels of IL-6 and hemostatic
status in acute ischemic stroke.
In our study, IL-6 levels were significantly ele-
vated early after stroke. This observation is con-
sistent with previous studies8-10 which suggest
that IL-6 may play an important role in the
inflammatory changes that occur following brain
ischemia and the subsequent tissue damage.
Despite a significant increase in IL-6 levels,
circulating levels of TAT (a reflection of systemic
procoagulant activity18) did not correlate with
IL-6. This observation supports the hypothesis
that IL-6 production is a localized inflammatory
response to acute hypoxic-ischemic injury and is
not related to enhanced thrombin activity or in-
travascular hypercoagulation status.
In this study we found that mean TAT levels
shortly after stroke were mildly elevated (3.4
ng/mL), an observation similar to a previous re-
port by Geiser et al. (2.9 ng/mL).19 These findings
suggest that thrombin formation is only partially
suppressed, despite adequate anticoagulation, in
patients with cerebrovascular events with pro-
sthetic heart valves. This is present in atherogenic
or lacunar subtypes, suggesting increased procoa-
gulant activity in patients with cardioembolism
and different pathophysiology of each subtype.
Even though there was no statistical difference in
IL-6 levels among the three different subtypes, the
mean value of IL-6 was highest in the cardiogenic
type, an observation that needs to be studied fur-
ther using a large number of patients of different
subtypes.
Although the importance of the thrombotic
process and fibrin metabolism in stroke has been
recognized for years, the role of fibrinolytic
abnormalities have not been clearly delineated,
probably because of the heterogeneous nature of
stroke syndrome and because of the variety of in
Table 5. Correlation Coefficients (r) Among Various Parameters in the Patients with Acute Ischemic Stroke
IL-6 PAP TAT PAI-1
Age 0.284 (n = 46) 0.167 (n = 46) 0.188 (n = 46) 0.073 (n = 45)
IL-6 1 0.223 (n = 46) 0.131 (n = 46) - 0.083 (n = 45)
PAP 1 0.455* (n = 46) 0.061 (n = 45)
TAT 1 0.264 (n = 45)
PAI-1 1
*p = 0.0015, p = 0.0787 (Spearman correlation coefficients).
Abbreviations: see Table 2.
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vitro methods for assessing fibrinolysis.
The recent development of specific immuno-
assays including t-PA,20 PAI-1,21 and PAP22 allow
more advanced assessment of the fibrinolytic
system. In our study, IL-6 levels did not correlate
with fibrinolytic markers, whereas there were
significant correlations between procoagulant TAT
and fibrinolytic markers (PAP and PAI-1). These
findings reflect systemic derangements of both the
clotting and fibrinolytic processes in stroke that
do not involve IL-6.
The proinflammatory cytokines are produced
not only by endothelial cells, monocytes, fibro-
blasts and T-lymphocytes,23,24 but also by micro-
glia25 and astrocytes.26 Localized inflammatory
response to acute brain lesion may have multiple
local and systemic effects that modulate the
disease course, including cytotoxicity,27 astrocyte
proliferation,28 and leukocyte activation.29 Re-
cently, Johansson et al.30 reported that neuroendo-
crine disturbances are often profound shortly after
stroke, and cytokines including IL-6 seem to be
important modulators of these disturbances. Vila
et al.31 have also assessed the implication of IL-6
in early neurological worsening in ischemic
stroke. More directly, IL-6 infusion has been
shown to stimulate coagulation32 and to signifi-
cantly correlate with coagulation markers.33 On
the other hand, IL-6 levels during the acute phase
should be interpreted with caution because the
pattern of the related changes depends on the
disease severity. Other contributing factors can
also affect the coagulation system.
34,35
Taken
together, these results suggest that elevated proin-
flammatory cytokines during the initial hours of
ischemic stroke may either be an independent
pathogenetic factor or the consequence of the
thrombotic event, with no relationship to the
procoagulant or fibrinolytic states.
Further investigation into the role of IL-6 in
stroke may provide a basis for new therapies of
stoke prevention or treatment.
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